IL2 and nonpapillary renal cell carcinoma: Tumour-specific TCR-T engineered products have been developed for HERV-derived proteins, and a first-in-human phase 1 dose escalation trial of HERV-E TCR-T plus IL2 has been performed in 11 metastatic ccRCC patients [115].